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ABSTRACT
The genome is traditionally viewed as a time-independent source of information; a paradigm that drives
researchers to seek correlations between the presence of certain genes and a patient’s risk of disease.
This analysis neglects genomic temporal changes, which we believe to be a crucial signal for predicting
an individual’s susceptibility to cancer. We hypothesize that each individual’s genome passes through an
evolution channel (The term channel is motivated by the notion of communication channel introduced
by Shannon1 in 1948 and started the area of Information Theory), that is controlled by hereditary,
environmental and stochastic factors. This channel differs among individuals, giving rise to varying
predispositions to developing cancer. We introduce the concept of mutation profiles that are computed
without any comparative analysis, but by analyzing the short tandem repeat regions in a single healthy
genome and capturing information about the individual’s evolution channel. Using machine learning
on data from more than 5,000 TCGA cancer patients, we demonstrate that these mutation profiles
can accurately distinguish between patients with various types of cancer. For example, the pairwise
validation accuracy of the classifier between PAAD (pancreas) patients and GBM (brain) patients is 93%.
Our results show that healthy unaffected cells still contain a cancer-specific signal, which opens the
possibility of cancer prediction from a healthy genome.
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Main
The human genome has evolved over time by an interplay of mutational events. An enhanced understand-
ing of the genome’s evolution has numerous direct and practical applications in improving healthcare,
discerning ancestry, materializing DNA storage and designing synthetic biology devices for computation.
Traditionally, the genome has been viewed as a time-independent source of information, and hence much
of the genomic research has been focused on discovering variants that cause a certain phenotype. Linkage
studies have discovered genes for Mendelian diseases such as Cystic Fibrosis2, Huntington disease3,
Fragile-X syndrome4 and many others5 by investigating genetic variants across families. For more com-
plex diseases, Genome Wide Association Studies (GWAS)6 can be used to discover large amounts of
risk factors working in conjunction. The broader scope of GWAS has led to the discovery of several new
genes and pathways7, but many diseases still remain unexplained. Instead of searching for disease-causing
variants, we view the genome as a time-dependent signal, searching for indicators for how the genome is
mutating over time. This gives rise to the following question - What are the possible ways to measure the
evolution of mutations? Put differently, how can we quantify the accumulation of mutations in the genome
of an individual?
Our approach for extracting time-dependent information about a person’s mutation history is to focus
on the tandem repeat regions of this person’s healthy genome. We have studied two types of mutations
in the genome: tandem duplications and point mutations. Tandem duplications involve the consecutive
repetition of a subsequence (e.g. TCAT G→ TCATCAT G). Point mutations, which include substitutions,
insertions, and deletions, are single changes in the DNA (e.g. ACT G→ ACAG). When these two processes
occur in the same location, point mutations can propagate through tandem duplications, leaving a change
in the repeated sequence (see Figure 1a and Methods section). This allows us to construct a likely
history of tandem duplications and point mutations. Slippage events can cause regions with many tandem
duplications8, which are a convenient locations to observe this interaction between mutation processes. In
a sense, these tandem repeats regions are a nature given repetition error-detecting code9, where the point
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mutation errors in the copies store information about the history of the evolution of these regions. These
repeat regions effectively characterize an evolution channel, which can shed light on the accumulation of
mutations in the genome.
Cancer Genomics
Cancer is currently the second leading cause of death worldwide10. Cancer is caused by an intricate
mixture of complex factors whose inter-relations are not well understood. While the roles of environmental
and hereditary factors are well accepted, recent studies suggest that two-thirds of the mutations in human
cancers are caused by replication errors11.
Most GWAS studies on cancer risk have focused on differences between healthy (i.e., normal) and
tumor DNA samples, namely in Single Nucleotide Polymorphisms (SNPs) and Copy Number Variations
(CNVs). These studies have discovered tumor suppressor genes like BRCA1, BRCA2, TP53 and onco-
genes like HER2 and RAs family12. Previous work has also shown that tumor genomes have significantly
more genes with repeat instabilities, linking microsatellite instability to colorectal13 and other cancers
13–18. Another recent approach identified 21 signatures for mutational processes in human cancer using
healthy genome based on 96 substitution classifications that were defined by 6 single base substitution
classes and the sequence context left and right of the mutated base19.
Unlike previous works, we aim to study cancer risk factors while using a healthy genome, without
using the genome of the tumor itself, which opens the door to cancer prediction and risk assessment.
To do this, we analyzed tandem repeat region data in different cancer types from The Cancer Genome
Atlas (TCGA)20. We estimated the number of point mutations (m) and tandem duplications (d) in each
tandem repeat region by predicting the evolutionary history of those regions21, 22 (see Figure 1a). We
used the aggregate of this evolution information to form what we call the mutation profile of the genome.
We then used a gradient boosting algorithm to learn the association between these mutation profiles and
the probability of developing specific cancers23. The association between the mutation profile and the
cancer-type signifies the presence of a cancer-type “signal” in the mutation profiles of the healthy genome,
3/30
.CC-BY-NC-ND 4.0 International licenseIt is made available under a 
(which was not peer-reviewed) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity.
The copyright holder for this preprint. http://dx.doi.org/10.1101/517839doi: bioRxiv preprint first posted online Jan. 11, 2019; 
which could be useful for future cancer prediction and early cancer detection.
Results
We hypothesized that different genetic mutation processes accounted for varying risks of developing cancer,
and that these processes would leave detectable signals in an individual’s profile. Rigorous verification
of this hypothesis would require DNA samples from cancer patients before the onset of their cancer.
Such a dataset is not currently available, but blood derived DNA is accessible on The Cancer Genome
Atlas (TCGA)20, and closely resembles the DNA of cancer patients before they developed the disease.
From TCGA, we gathered 3874 unamplified blood derived WXS samples which spanned 12 cancers:
TCGA-GBM, LUAD, LUSC, PRAD, PAAD, STAD, HNSC, BLCA, KIRC, LGG, SKCM, THCA (Table
1A (Column 2), Supplementary Files 1-12). We used microsatellites (tandem repeats with pattern lengths
≤ 10 bp) with at most 100 repeats to obtain mutation profiles (see Methods, Figure 1).
Pairwise Cancer Classifiers - Using only Blood Derived Normal Samples
Here we use 3843 unamplified blood-derived normal samples spanning 11 cancers for our analysis (see
Table 1A, Supplementary Files 1-12). We did not use the blood derived samples from TCGA-KIRC in this
analysis as we only had 31 samples for KIRC which was not enough to construct a reliable classifier. We
verified the existence of cancer-type signals within the mutation profiles of blood-derived normal samples
by training cancer classifiers using xgboost23 and testing their accuracy on separate validation-set data
(see Methods, Code/Software, Figure 2).
As can be seen in Figure 2, mutation profiles of blood-derived normal DNA of GBM patients shows
strongly distinctive signals from the rest of the tested cancers with classification accuracies ranging in
between 75% for HNSC to as high as 93% for SKCM and PAAD. A similar observation is made for both
SKCM and PAAD as they are distinguishable from all of the other cancers with more than 71% accuracy.
For other cancers - STAD, BLCA, LGG, PRAD, LUAD, THCA, LUSC, HNSC, the distinguishing signal
is much weaker for many cancers. For example, LGG when compared against PRAD, BLCA, LUAD,
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LUSC gives pairwise accuracies of 59%, 64%, 59% and 58% respectively. Cancers with risk factors that
emit different mutation profiles are easier to distinguish, resulting in more accurate classifiers. Hence,
accuracy gives a notion of distance on the scale of 50% (close, indistinguishable) to 100% (far, different).
The order of the cancers in the display minimizes the distances between neighboring cancers using the
travelling salesman problem (TSP)24, giving a likely low dimensional projection of the features being
learned by the classifiers. The observed accuracies and specificity/sensitivity observed in Figure 2 confirm
the presence of cancer-type signal in the blood-derived normal DNA.
The clustering of cancers in Figure 2 led us to define four cancer classes: Class 1 = [GBM], Class 2 =
[SKCM], Class 3 = [PAAD] and Class 4 = [LUAD, LUSC, PRAD, STAD, HNSC, BLCA, LGG, THCA].
The seriation matrices in Figure 3a represent the binary classifier accuracies and sensitivity/specificity for
these different classes.
Cancer Classification Profiles
To assess a patient’s propensity of developing a class of cancers, we trained a multiclassifier for the
four cancer classes using gradient boosting. This classifier uses a mutation profile to predict the relative
probability of each class of cancer. Figure 3b shows the mean and standard deviation of these probabilities
when tested on patients from each cancer class. Class 1, 2, and 3 all give large probabilities for their
respective classes. Classes 2 and 3 give weaker signals because they are closer to Class 4 than Class 1 is
(see Figure 3a). Individuals in Class 4 in the test set have similar scores for Classes 2, 3 and 4, showing
that Class 4’s signal is not very distinct from Classes 2 and 3. This can again be attributed to the closeness
of Class 4 to both Class 2 and Class 3 in the seriation diagram in Figure 3a. Supplementary Figure 6
gives the classification profile for Class 4 individuals when training only on Classes 1, 2 and 3 individuals.
Again, Class 4 seems to imitate Classes 2 and 3, but the high standard deviation in Class 1 probability
suggests Class 4 cancer patients can also have a high probability for Class 1 cancers.
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Effect of Adding NAT samples on classifiers
Recent studies have shown positive associations of Solid Tissue Normal (Normal Adjacent to Tumor
(NAT)) samples on TCGA with the tumor DNA of cancer patients25, 26. We added 687 unamplified NAT
samples as mentioned in Table 1A (Column 3) in our analysis to check if their presence is useful in
discovering a stronger cancer-type signal. More precisely, we combined the 3874 blood-derived and 687
NAT samples to construct the pairwise classifiers. Here, we also covered TCGA-KIRC as now we had
210 (179 NAT and 31 blood-derived) samples that were enough to build reliable classifiers. We didn’t
observe any significant improvement in cancer signal detection by adding NAT samples over only using
blood-derived normal samples and found the same cancer classes that we discovered previously (see
Figure 4a, Supplementary Figure 7). Further, we found that TCGA-KIRC belonged to the same class as
TCGA-GBM showing strongly distinctive signal from the other 10 cancers (see Figure 4a, Supplementary
Figure 7).
Analysis of Amplified Samples
Amplification techniques have been shown to bias tandem repeat information27, especially in TCGA data28.
To control for this, we separately analyzed amplified samples. Figure 4b shows the seriation diagrams
for accuracy and sensitivity/specificity of pairwise classifiers built using 525 samples amplified by MDA
technology. Because of the limited data, this test only covered TCGA-GBM (brain), TCGA-OV (ovary)
and TCGA-LAML (leukemia) and both the normal DNA types, i.e. blood-derived and solid tissue normal
(NAT) were used (Table 1B, Supplementary Files 13-15). The high accuracy and sensitivity/specificity
values in these diagrams suggest a strong cancer-type signal in the mutation profiles of the healthy DNA.
Further, we also generated the classification profiles using these amplified samples for individuals with
brain, ovary and leukemia cancer. Figure 4c shows the mean and standard deviation of the predicted cancer
probabilities for these three populations. The highest probability cancers correspond with the cancers that
the patients were diagnosed with, affirming that healthy DNA contains a cancer-type signal.
Genome analysis for the results presented in Figures 2-5 and Supplementary Figures 6-14 was done
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using samtools29 (see Methods, Code/Software) and the pipeline presented in Figure 1b. We also verified
these results for unamplified samples by using another genome analysis tool for short tandem repeats
(STR)- hipSTR30 that only detects tandem repeats with pattern lengths atmost 6 (see Supplementary
Figure 15).
Driver Genes
Studies in the past have identified driver genes like TP53, BRCA-1, BRCA-2, etc. We considered 723
such genes that are listed in Supplementary File 16 obtained from Cancer gene census - COSMIC31, 32.
To test whether these regions provided special information, we filtered our mutation profiles to only
use tandem repeats that overlapped with driver gene regions. We conducted this experiment for the 4561
unamplified samples and 525 amplified samples separately. Figure 5 shows a comparison the classifiers
trained on these filtered mutation profiles and mutation profiles which contain all the features except those
in the filtered profiles. Darker cells in this figure correspond to large differences in the accuracy of the
classifiers, indicating that these signals exist outside of driver gene regions. We notice these darker cells
especially for TCGA-PAAD (pancreas) and TCGA-SKCM (skin). We also see noticeable differences
when TCGA-OV (ovary) is compared against TCGA-GBM (brain) and TCGA-LKCM (leukemia). The
driver-gene classifiers always performed worse than the classifiers trained on the rest of the genome,
indicating that the signal exists both inside and outside driver gene regions.
Discussion
Early Cancer prediction
We have shown that the mutation profiles of the blood-derived normal genomes of cancer patients contain
a cancer-type signal (Figures 2 & 3). It is reasonable to assume that the mutation profiles of cancer-free
patients may also contain these signals, and we can use our classifier to quantify their presence. The cancer
classification profiles given by this classifier could be used to screen individuals for those who may benefit
from more comprehensive and expensive cancer detection tests.
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Accumulation of Mutations
Searching for information-containing features within 3 billion nucleotides is a formidable task. This has
traditionally been simplified by comparing individuals to extract variants, which compresses the genome
into a smaller set of features to analyze. These differences, known as SNPs and CNVs, are central to both
Mendelian studies5 and GWAS6, 7, 12.
This form of genome compression loses crucial information about how the genome is changing by
only considering differences in the genome’s current state. Every individual’s genome passes through a
distinct evolution channel that is controlled by hereditary, environmental and stochastic factors. These
evolution channels differ among the population and can give rise to different risks of disease, but we
cannot easily identify these differences from the single-generation SNP and CNV analysis used in GWAS.
Mendelian studies may provide insight into inter-generational processes, but do so at the cost of requiring
inter-generational data, which severely limits the scope of a feature search. Even with additional data,
Mendelian studies still lack the ability to detect differences in mutation processes that occur throughout
one’s lifetime.
Mutation profiles are generated without any comparative analysis, reducing the data-demand. Instead,
the tandem repeat regions in a single genome provide a window into its history, capturing information
about the individual’s evolution channel. This ability to reconstruct a genome’s history from repeat regions
is lost when studies only view differences between individuals. The use of mutation profiles expands our
access to time-dependent traits which may be essential to understanding developed diseases like cancer.
Sequencing Technology Limitations
TCGA samples are obtained from Illumina platforms with a coverage depth 30-40X. The read lengths
used are short ranging between 100-500 bp. This poses a problem in the detection of longer tandem
repeats33–35. In our analysis, we only used repeats with pattern lengths ≤ 10 bp and number of copies not
greater than 100.
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Methods
WXS data
We used exome data from “blood derived normal” and “solid tissue normal” samples in the TCGA20
database, details about which are provided in the Supplementary Files 1-15. The BAM file for each sample
was aligned against hg38. All the autosomes from each sample were recovered using samtools29.
Algorithms
Our algorithms are partitioned to Part A and Part B (see Fig. 1b). Part A is only performed once, where
Part B is performed whenever cancer prediction is required. In Part A, a dataset of healthy DNA is first
processed by the Benson21 and Tang et al.22 algorithms to deduce the mutation profiles. Then, these
vectors are aligned by a dynamic programming algorithm to resolve missing regions. Finally, the aligned
vectors are fed into a training algorithm to produce a classifier. In Part B, this classifier is applied over any
individual’s genome, to assess the overall probability to contract any of the cancer in question.
Tandem Repeat Detection and Duplication History Estimation
Tandem duplications are consecutively repeated patterns caused by replication slippage events36, 37,
in which a pattern is duplicated next to the original. For example, the following shows two tandem
duplications of length 4, where the duplicated part is highlighted in bold. The underlined segment is the
microsatellite or repeat region.
ATGACGTGAGT⇒ ATGACGTGAGTGAGT⇒ ATGACGTGAGTGAGTGAGT. (1)
The pattern of a region is the short strand which repeats itself. The copy number d of a repeat region
indicates the number of times that the pattern is repeated. For example, the pattern of the underlined repeat
region in the right hand side of (1) is GTGA, and its copy number is 3.
Microsatellites are usually accompanied by various types of errors: substitutions (replacement of one
nucleotide by another), deletions (omission of a nucleotide), and insertions (addition of a nucleotide). The
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total number of substitutions, deletions, and insertions in a repeat region is called the error number m. For
example, the following shows the contamination of (1) by 1 substitution, 1 deletion, and 1 insertion.
ATGACGTGAGTGAGTGAGT⇒ ATGACGTTAGTGAGTGAGT
⇒ ATGACGTTAGGAGTGAGT
⇒ ATGACGTTAGGAGTGAGGT. (2)
Clearly, the copy number of (2) is 3 and its error number is 3, and hence its mutation index is (m,d) = (3,3).
In the first step of Part A we use the Benson Tandem Repeat Finder to detect repeats with consensus
pattern size at most 10 and copy number at most 100. These size limitations mean we only consider
regions smaller than 1000 nucleotides. The single block version of the duplication history estimation
algorithm given in Tang et al.22 was then applied to each tandem repeat region to obtain the respective
mutation index = (m,d). The aggregation of these (m,d) values gives a vector twice the size of the number
of repeat regions, which we call an individual’s mutation profile. Since, TCGA data is WXS, we only
calculated a unique mutation profile of an individual’s exome.
Alignment
Following the completion of the Benson and Tang et al. algorithms, it was sometimes the case that certain
repeat regions appeared in some patients and did not appear in others. In addition, minor differences
were observed in the patterns of identical repeat regions in different individuals. As a result, a technical
difficulty arose in handling the input to the learning algorithm. Consider the following two patients, in
which the repeat regions are underlined.
Patient 1: AAAAAAACGATCGAGTTCAGTATTGCCGCGAGCG
Benson
Tang et al.
=⇒ (A : (0,7), CG : (1,4))
Patient 2: AAAAAAAACGACGTACGTACGTATTGCCGCGCG
Benson
Tang et al.
=⇒ (A : (0,8), CGTA : (0,3), CG : (0,3))
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The success of machine learning depend on the detection of patterns in specific positions of feature
vector, so entries which correspond to the same repeat region must also be placed in the same position for
all inputs. This is clearly not the case in the above example, in which the second entries of the vectors
correspond to different repeat regions.
This issue is resolved by using a dynamic programming alignment algorithm. In this algorithm, a
similarity score is computed recursively for each possible alignment, and the alignment which leads to the
best possible score is chosen. Each possible alignment is defined as the sum of normalized edit-distances1
between the patterns of all respective pairs. Further, the distance between any pattern and a “missing
pattern”, denoted by ‘–’ below, is defined as 0.4. Namely, two patterns whose respective normalized edit
distance is less than 0.4 were considered to be equal for the sake of the alignment. For example, the
vectors above are aligned in the following way.
(A : (0,7), CG : (1,4))
Alignment
=⇒ (A : (0,7), – ,CG : (1,4))
(A : (0,8), CGTA : (0,3), CG : (1,3))
Alignment
=⇒ (A : (0,8), CGTA : (0,3),CG : (1,3)) (3)
The score for the alignment (3) is de(A,A)+de(–,CGTA)+de(CG,CG) = 0+0.4+0 = 0.4, where de
denotes edit distance. For comparison, the alternative alignment
(A : (0,7), CG : (1,4))
Alignment
=⇒ (A : (0,7), CG : (1,4) , – )
(A : (0,8), CGTA : (0,3), CG : (1,3))
Alignment
=⇒ (A : (0,8), CGTA : (0,3),CG : (1,3)) (4)
has score of de(A,A)+ de(CG,CGTA)+ de(–,CG) = 0+ 2/3+ 0.4 ≈ 1.06, and hence (3) is preferred
over (4).
The mutation profile of each individual was aligned against the mutation profile of the reference
genome (hg38) by using the method that is mentioned above. The repeat regions that were missing in the
1That is, the minimal number of insertions, deletions, and substitutions that are required to transform one pattern to the
other, divided by the average length of the sequences.
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reference genome were omitted from these aligned mutation profiles. Further, given the aligned mutation
profiles, every ‘–’ is replaced by (0,0). This gave aligned mutation profiles of the same size that can now
be used as features for the learning part described next.
Machine Learning
The aligned mutation profiles were used as features for the learning algorithm. Machine learning classifiers
for distinguishing cancers were obtained using two approaches:
Pairwise Classifiers
We trained a binary classifier for every pair of types of cancer, generating
(12
2
)
= 66 pairwise classifiers
for unamplified samples and
(3
2
)
= 3 pairwise classifiers for amplified samples. The accuracy in either of
those classifiers is used as a measure for the “uniqueness” of the mutation profiles that cause a certain type
of cancer, and can additionally be seen as a distance measure between different types of cancer. We used
xgboost23 algorithm at default parameters with max-depth = 2, and performed 4-fold validation to build
each of these pairwise classifiers.
Multiclassifier
This was built using xgboost ‘multi:softprob’ parameter with max-depth = 2 and predicted the probability
of all the cancers simultaneously. Again 4-fold cross validation was performed to avoid over-fitting.
Code/Software
The code and necessary documentation for the pipeline used is available at http://paradise.
caltech.edu/~sidjain/Codes.tar.gz.
Data Availability
The BAM files for WXS samples of cancer patients used in the study were obtain from The Cancer
Genome Atlas (TCGA)20. These files have controlled access and cannot be availed publicly. However,
request to access TCGA controlled data can be made via dbGap38 (accession code: phs000178.v1.p1).
The file names for the analyzed samples are given in Supplementary Files 1-15.
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Figure 1. (a) Two different evolution histories for the tandem repeat region ACGTACGTACATAGAT with pattern length 4
and repeat region length 16. In History 1, only 2 point mutations were needed (marked with green and red respectively). In
History 2, 3 point mutations were needed: 1 marked with green and 2 marked with red. In our approach, we would consider
History 1 to be more likely as it involves lesser number of point mutations. Therefore, for this tandem repeat region we have
that m = 2 and d = 4. (b) The workflow of our algorithm. In Part A a classifier is trained based on the mutation profiles
generated from the healthy DNA of cancerous individuals. This part in only performed once per training set. In Part B, the
resulting classifier is applied over a given genome to assess an individual’s inclination of developing different cancers.
18/30
.CC-BY-NC-ND 4.0 International licenseIt is made available under a 
(which was not peer-reviewed) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity.
The copyright holder for this preprint. http://dx.doi.org/10.1101/517839doi: bioRxiv preprint first posted online Jan. 11, 2019; 
A: Unamplified Samples
Cancer Blood Derived Normal Solid Tissue Normal
SKCM 344 0
PAAD 153 31
STAD 396 49
BLCA 393 20
PRAD 440 56
LGG 513 0
LUAD 411 102
THCA 432 68
LUSC 316 180
HNSC 190 0
GBM 255 2
KIRC 31 179
B: Amplified Samples
Cancer Blood Derived Normal Solid Tissue Normal
GBM 171 0
LAML 0 135
OV 160 59
Table 1. (A) Number of unamplified healthy samples used for each cancer type in the study showing the number of blood
derived normal and solid tissue normal samples. In total, the number of blood derived healthy samples are 3874 and the tissue
derived healthy samples are 687. The sample information is provided in Supplementary Files 1-12. (B) Number of amplified
healthy samples used for each cancer type in the study showing the number of blood derived normal and solid tissue normal
samples. In total, the number of blood derived healthy samples are 331 and the tissue derived healthy samples are 194. The
sample information is provided in Supplementary Files 13-15.
19/30
.CC-BY-NC-ND 4.0 International licenseIt is made available under a 
(which was not peer-reviewed) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity.
The copyright holder for this preprint. http://dx.doi.org/10.1101/517839doi: bioRxiv preprint first posted online Jan. 11, 2019; 
Figure 2. The matrix on the left contains the pairwise validation accuracies of classifiers built by using 3843 blood-derived
normal DNA samples covering 11 different cancer types. These cancer types are TCGA-SKCM (skin), PAAD (pancreas),
STAD (stomach), BLCA (bladder), PRAD (prostate), LGG (brain_lgg), LUAD (lung), THCA (thyroid), LUSC (lung_sq),
HNSC (head_neck), GBM (brain). Each cell in the accuracy seriation matrix represents the average validation accuracy of the
binary pairwise classifiers. Each pairwise classifier between cancer X and cancer Y (X6=Y) was constructed using 4-fold
cross-validation with patients of each cancer type. These accuracies can be interpreted as distances. The darker the cell, farther
are the cancers being compared. The darker rows corresponding to brain, skin and pancreas are indicative of the presence of
cancer-type signal in the blood-derived normal (healthy) DNA of cancer patients. The diagonal entries in the seriation matrix
represent the accuracies when half of the patients of cancer X were labeled 0 and half of the patients of the same cancer X were
labeled 1. As one can expect, the average test accuracy for such classifier should be around 50%. The value in the cell
corresponding to the row “pancreas” and the column “prostate” signifies that an average of 74% of the people were correctly
classified in each validation pass. The matrix on the right, contains the sensitivity/specificity values. Each cell in the
sensitivity/specificity seriation matrix represents the sensitivity value when the row cancer is considered positive and the
column cancer is considered negative. It can also be regarded as specificity when the row cancer is considered negative and the
column cancer is considered positive. Sensitivity is defined as T P/(T P+FN) and specificity is defined as T N/(T N +FP),
where T P = True Positive, FP = False Positive, T N = True Negative, FN = False Negative. A value of .77 in the row “prostate”
and the column “pancreas” means that 77% of the prostate patients in the test set were truly classified as prostate type
(sensitivity when prostate is considered positive). A value of .73 in the row “pancreas” and the column “prostate” means that
73% of the pancreas patients in the test set were truly classified as pancreas type (specificity when prostate is considered
positive). The seriation ordering is obtained by solving TSP (i.e., the Travelling Salesman Problem) exhaustively24.
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(a)
(b)
Figure 3. (a) These seriation matrices show 4-fold validation accuracy and sensitivity/specificity for the four main clusters
of cancers in Figure 2 generated using 3843 blood-derived normal samples. Class 1 = (brain), Class 2 = (skin), Class 3 =
(pancreas), Class 4 = (stomach, bladder, prostate, brain_lgg, lung, thyroid, lung_sq, head_neck). (b) Mean and standard
deviations for the cancer classification profiles of individuals in Class 1, Class 2, Class 3 and Class 4 (viewing left to right). To
generate these profiles, we a trained multiclassifier on all four classes of cancers using gradient boosting. We then used this
multiclassifier to obtain cancer classification profiles for a different set of individuals reported the average results for each
cancer class. Class 1 individuals show a high probability for Class 1 cancers. Class 2 and Class 3 individuals also show a higher
probability for their respective classes, but with a slightly weaker signal. Class 4 individuals show similar probabilities for
Class 2, Class 3 and Class 4.
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(c)
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Figure 4 (preceding page). (a) The matrix on the left contains the pairwise validation accuracies of classifiers built
by using 4561 unamplified samples covering both blood-derived and solid tissue normal DNA of 12 different cancer types.
These cancer types are TCGA-SKCM (skin), PAAD (pancreas), STAD (stomach), BLCA (bladder), PRAD (prostate), LGG
(brain_lgg), LUAD (lung), THCA (thyroid), LUSC (lung_sq), HNSC (head_neck), GBM (brain), KIRC (kidney). (b) Classifier
accuracies and sensitivity/specificity when training and testing is done using amplified samples only. The cancers covered here
are TCGA-GBM (brain), TCGA-OV (ovary) and TCGA-LAML (leukemia). There is a strong signal distinguishing all these
cancer types. We speculate that TCGA-KIRC would behave similarly to TCGA-GBM, since these cancers are similar in Figure
4a. (c) Mean and standard deviation for the cancer classification profiles of individuals belonging to TCGA-GBM (brain),
TCGA-OV (ovary) and TCGA-LAML (leukemia). These classification profiles are obtained by building a multiclassifier using
gradient boosting. The multiclassifier is obtained by training only on amplified healthy samples of brain, ovary and leukemia
cancers on TCGA. The testing is done on a separate set of amplified samples for these cancers. It can be seen that brain, ovary
and leukemia cancer patients in the test set are showing a higher probability for the respective cancer using their healthy DNA
mutation profile.
Figure 5. A comparison of classifiers trained on mutation profiles restricted to known driver-gene regions and those
restricted to non-driver-gene regions. Darker cells represent a larger difference in the testing accuracies of the classifier,
indicated by the scale. This experiment was performed on unamplified (left) and amplified (right) samples separately. The
uneven coloring suggests that some cancer-type signals exist more primarily in driver-gene regions than others.
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Figure 6. (Supplementary) Cancer classification profile for Class 4 individuals when the multiclassifier was trained
only using Class 1, Class 2 and Class 3 samples mentioned in Figure 3a. This shows a stronger association of Class 4 with
Class 2 and Class 3 than Class 1. However the high standard deviation for Class 1 also means that some individuals in Class 4
have a stronger association with Class 1 than Class 2 and Class 3.
Supplementary Information
We replicated our experiments with only error number m and only copy number d values in the mutation
profiles. These experiments gave results similar to the complete profiles, suggesting that both m and
d contain cancer-type signals. Supplementary Figure 9 shows the associated pairwise accuracies and
sensitivity/specificity for cancers with 3843 blood-derived normal unamplified samples when only d was
used in the mutation profile and Supplementary Figure 10 shows the associated pairwise accuracies and
sensitivity/specificity when only m was used. Supplementary Figures 11 and 12 show the plots using all
the 4561 unamplified samples. Supplementary Figures 13 and 14 show the plots for the 525 amplified
samples..
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(a)
(b)
Figure 7. (Supplementary) (a) These seriation matrices show 4-fold validation accuracy and sensitivity/specificity for
the four main clusters of cancers in Figure 4a where all the 4561 unamplified samples were used. Class 1 = (brain, kidney),
Class 2 = (skin), Class 3 = (pancreas), Class 4 = (stomach, bladder, prostate, brain_lgg, lung, thyroid, lung_sq, head_neck). (b)
Mean and standard deviations for the cancer classification profiles of individuals in Class 1, Class 2, Class 3 and Class 4
(viewing left to right). To generate these profiles, we a trained multi-classifier on all four classes of cancers using gradient
boosting. We then used this multi-classifier to obtain cancer classification profiles for a different set of individuals reported the
average results for each cancer class. Class 1 individuals show a high probability for Class 1 cancers. Class 2 and Class 3
individuals also show a higher probability for their respective classes, but with a slightly weaker signal. Class 4 individuals
show similar probabilities for Class 2, Class 3 and Class 4.
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Figure 8. (Supplementary) Cancer classification profile for Class 4 individuals when the multiclassifier was trained
only using Class 1, Class 2 and Class 3 samples shown in Supplementary Figure 7. This shows a stronger association of Class 4
with Class 2 and Class 3 than Class 1. However the high standard deviation for Class 1 also means that some individuals in
Class 4 have a stronger association with Class 1 than Class 2 and Class 3.
Figure 9. (Supplementary) Accuracies and sensitivity/specificity for the pairwise classifiers when only the copy
number (d) information was used in the mutation profile for the 3843 WXS blood-derived unamplified samples mentioned in
Table 1A. Notice that like Figure 2, we again find strong distinguishing signals for brain, pancreas and skin cancers as can be
seen by the darker rows corresponding to these cancers.
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Figure 10. (Supplementary) Accuracies and sensitivity/specificity for the pairwise classifiers when only the error
number (m) information was used in the mutation profile for the 3843 WXS blood-derived unamplified samples mentioned in
Table 1A. Notice that like Figure 2, we again find strong distinguishing signals for brain and skin cancers as can be seen by the
darker rows corresponding to these cancers. However unlike Figure 2, the signal for pancreas cancer is not as strong.
Figure 11. (Supplementary) Accuracies and sensitivity/specificity for the pairwise classifiers when only the copy
number (d) information was used in the mutation profile for the 4561 WXS unamplified samples that comprised both
blood-derived and solid tissue normal type DNA as mentioned in Table 1A.Notice that like Figure 4a, we again find strong
distinguishing signals for (brain,kidney), pancreas and skin cancers as can be seen by the darker rows corresponding to these
cancers.
27/30
.CC-BY-NC-ND 4.0 International licenseIt is made available under a 
(which was not peer-reviewed) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity.
The copyright holder for this preprint. http://dx.doi.org/10.1101/517839doi: bioRxiv preprint first posted online Jan. 11, 2019; 
Figure 12. (Supplementary) Accuracies and sensitivity/specificity for the pairwise classifiers when only the error
number (m) information was used in the mutation profile for the 4561 WXS unamplified samples that comprised both
blood-derived and solid tissue normal type DNA as mentioned in Table 1A.Notice that like Figure 4a, we again find strong
distinguishing signals for (brain,kidney) and skin cancers as can be seen by the darker rows corresponding to these cancers.
However, unlike Figure 4a, the signal for pancreas cancer is not as strong.
Figure 13. (Supplementary) Accuracies and sensitivity/specificity for the pairwise classifiers when only the copy
number(d) information was used in the mutation profile for the 525 WXS amplified samples mentioned in Table 1B. Notice
that like Figure 4b, we again find strong distinguishing signals for all the three cancers.
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Figure 14. (Supplementary) Accuracies and sensitivity/specificity for the pairwise classifiers when only the error
number (m) information was used in the mutation profile for the 525 WXS amplified samples mentioned in Table 1B. Notice
that like Figure 4b, we again find strong distinguishing signals for all the three cancers.
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Figure 15. (Supplementary) Accuracies for the pairwise classifiers when hipSTR was used for STR detection.
hipSTR detects short tandem repeats with pattern lengths 6 or less. We used –min-reads 1 –def-stutter-model setting. Even
though hipSTR requires further trimming of mutation profiles to tandem repeats with pattern lengths ≤ 6, we were still able to
detect cancer-specific signals. The differences from Figure 4a in Figure 15 (for example: prostate and brain, prostate and
kidney, skin and pancreas) can be attributed to the fact that there are tandem repeat regions with pattern lengths greater than 6
that contained critical cancer-specific information. Further, we only used STRs that were commonly detected by hipSTR in all
the samples being analyzed. Therefore, the STRs that were not detected in some samples were not used in this analysis.
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